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To the Editor:
The recently published article by 
Scagliotti et al.1 reports the results of an 
explorative study performed on a subset 
of patients with bone metastatic lung 
cancer, enrolled in a large, prospec-
tive, phase III trial, which compared the 
efficacy of denosumab plus standard 
antineoplatic therapy versus zoledronic 
acid plus standard therapy. The results 
showed that denosumab-treated patients 
obtained a significant survival improve-
ment over zoledronic acid-treated ones. 
The greater potency of denosumab 
than zoledronic acid in decreasing 
bone turnover is conceivably the major 
mechanism responsible for the results 
obtained, so these data further underline 
the importance of targeting bone micro-
environment in the management of 
patients with metastatic cancer. In the 
two randomized clinical trials with the 
same design, conducted in patients with 
breast and prostate cancer,2,3 however, 
denosumab failed to demonstrate a sur-
vival advantage over zoledronic acid. 
How can we explain this discrepancy? 
All these trials showed that the greater 
bone turnover inhibition induced by 
denosumab led to a greater incidence 
of hypocalcemia than zoledronic acid. 
However, hypocalcemia was more fre-
quent in patients with bone lesions with 
a greater blastic component, that is, 
13% in prostate cancer versus 8.6% in 
lung cancer patients after denosumab 
(the frequency of hypocalcemia in the 
breast cancer trial was not reported). 
The consequence of hypocalcemia is 
secondary hyperparathyroidism and 
this condition can adversely affect the 
efficacy of bone resorption inhibitors 
by several mechanisms: (1) parathyroid 
hormone (PTH) increases the availabil-
ity of cytokines and growth factors in 
bone microenvironment, (2) PTH has 
an amino-terminal sequence homol-
ogy with PTH-related protein, a potent 
growth factor, and PTH-related pro-
tein and PTH bind to the same recep-
tor that is expressed in cancer cells. In 
an explorative analysis performed on 
the data of a multinational trial of bone 
metastatic prostate cancer patients who 
were randomized to receive zoledronic 
acid or placebo,4 secondary hyperpara-
thyroidism was a negative predictor 
of zoledronic acid efficacy in terms of 
survival. On these grounds, an interest-
ing hypothesis is that secondary hyper-
parathyroidism may limit the efficacy 
of denosumab. If this hypothesis is 
true, then a vitamin D supplementation 
tailored to counteract individual hypo-
calcemia can improve the drug efficacy 
in terms of survival. In the explorative 
study by Scagliotti et al.,1 therefore, it 
would be interesting to know whether 
the efficacy of denosumab versus zole-
dronic acid is improved in the patient 
subset that did not experience hypo-
calcemia after denosumab, as opposed 
to those patients developing this meta-
bolic disturbance.
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To the Editor:
The combination of platinum-
compounds and pemetrexed has 
recently become the standard of care 
in the first-line treatment of malignant 
pleural mesothelioma (MPM). Because 
not all the patients benefit, predic-
tive biomarkers of pemetrexed activ-
ity are critical for tailored treatments. 
However, pharmacogenetic studies on 
genotyping or expression profiles were 
controversial. A possible explanation 
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might be the use of a single methodol-
ogy for the study of a single factor ver-
sus several analyses evaluating multiple 
determinants of drug activity.
Because only few studies addressed 
this point, we appreciated the article by 
Mairinger et al.1 evaluating by means 
of both immunohistochemistry and 
quantitative polymerase chain reaction 
(qPCR), the expression of five folate 
pathway genes in 63 MPMs. This study 
suggested an association between high 
reduced folate carrier and low folylpo-
lyglutamate synthetase (FPGS) mRNA 
expression with overall survival, but 
not for thymidylate synthase (TS). 
However, no significant association 
was observed with objective response.
Conversely, we reported a cor-
relation of both TS mRNA and protein 
expression with overall survival in 99 
MPM patients who were given carbo-
platin + pemetrexed.2 Moreover, higher 
levels of TS were associated with a 
minor probability of disease control and 
progression-free survival. Similarly, 60 
patients with low TS protein expres-
sion benefited from pemetrexed + cis-
platin, but no correlation was found for 
mRNA levels.3 However, a recent study 
indicated a lack of correlation for both 
TS and FPGS protein expression in 85 
patients receiving pemetrexed as pri-
mary therapy.4
These discrepancies might be 
because of differential methods, treat-
ment heterogeneity, and relatively 
small or heterogeneous sample size. 
Because FPGS is essential for peme-
trexed polyglutamylation, which pro-
longs its intracellular retention, one 
would have expected that a low FPGS 
would be related to a poor survival. 
Mairinger et al.1 used a polyclonal 
anti-FPGS that was not tested in FPGS-
overexpressing or -deficient cells, and 
evaluated patients treated in first- and 
second-line with different regimens. 
Although qPCR is also a specific 
technique for the analysis of archived 
paraffin-embedded tissues, mRNA can 
differ from protein expression. This 
holds particularly true for FPGS, which 
undergoes extensive mRNA splicing, 
leading to multiple different RNA frag-
ments, and various truncated protein 
fragments or no protein.5 Splicing is an 
ubiquitous phenomenon, which might 
explain the counterintuitive association 
of low FPGS with longer survival and 
the lack of a relationship between FPGS 
protein and mRNA. Therefore, spliced 
variants should be tested in the valida-
tion of FPGS antibodies. Last but not 
least, future studies should evaluate the 
active drug metabolites, such as intra-
cellular pemetrexed polyglutamates, to 
obtain a complete picture of pharmaco-
kinetics or pharmacodynamics effects.
Another critical point consists of 
the evaluation of tumor heterogeneity 
and possible evolution of cancer cells 
after tumor relapse, which should be 
documented with multiple sampling of 
the single tumor and repeated biopsies.
In conclusion, we agree that 
observational studies can provide a 
strong rationale for future trials, but we 
believe that interlaboratory validation 
of techniques for sample collection or 
analysis, especially qPCR or immuno-
histochemistry, is essential. Moreover, 
larger and uniformly treated popula-
tions, according to powered statistical 
analysis and integration with functional 
data, are essential to validate the best 
markers for personalized treatment of 
MPM patients.
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In Response:
We appreciate the critical com-
ments to our article1 on predictors of 
pemetrexed response in malignant 
mesotheliomas by Zucali et al.2
The authors contrasted our find-
ing by their published study,2 where 
they found a correlation between low 
thymidylate synthase (TS) as evalu-
ated by immunohistochemistry (IHC) 
and mRNA, and better overall survival 
and longer progression-free survival 
in 99 malignant pleural mesothelioma 
(MPM) patients given carboplatin and 
pemetrexed treatment. In contrast to 
what they discussed in the letter, they 
personally investigated only TS and 
excition repair cross complementation 
group 1 (ERCC1). Their findings are 
not surprising, because several studies 
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